Asia Pac IPO & Placement Research, China biotech, Aequitas Research

Ke Yan, CFA, FRM

An inquisitive investment analyst with background in both finance and computing. Covering ECM research, biotech, market data analytics.

Asia Pac IPO & Placement Research, China biotech

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

Ambio Pharmaceuticals / Equity Capital Markets

AmbioPharm, a leading global peptide CDMO player, plans to raise up to USD 300m via a Hong Kong listing.The company ranked number four globally for the peptide CDMO which is a specialized segment in the landscape of the overall CDMO market. We like the company's market leadership and its growth. The company is monetizing its expertise by collaborating with biotech and pharmaceutical companies to develop peptide biosimilars benchmarking to block buster diabetes peptide drugs. With quality pre-IPO investors, experienced management team and interesting business model, we think investors should follow the IPO.

AmbioPharm, a leading global peptide CDMO player, plans to raise up to USD 300m via a Hong Kong listing.The company ranked number four globally for the peptide CDMO which is a specialized segment in the landscape of the overall CDMO market. We like the company's market leadership and its growth. The company is monetizing its expertise by collaborating with biotech and pharmaceutical companies to develop peptide biosimilars benchmarking to block buster diabetes peptide drugs. With quality pre-IPO investors, experienced management team and interesting business model, we think investors should follow the IPO.

AmbioPharm (昂博制药) Pre-IPO: Peptide CDMO Leader Turning Licensor